<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863511</url>
  </required_header>
  <id_info>
    <org_study_id>TUF-01</org_study_id>
    <nct_id>NCT01863511</nct_id>
  </id_info>
  <brief_title>Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure</brief_title>
  <acronym>TUF</acronym>
  <official_title>Primary Mode of Therapy in Acute Decompensated Heart Failure:Comparison Between Usual Care Plus Tolvaptan and Ultrafiltration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christ Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Christ Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients hospitalized with acute decompensated heart failure,volume removal remains the
      primary therapeutic objective. The current standard of care remains loop diuretics.The high
      likelihood of readmissions and poor outcomes highlights the need to examine and improve
      in-hospital protocols for these patients. Ultrafiltration allows for greater volume removal,
      less neurohormonal stimulation and greater sodium removal.However it is associated with
      increased costs, line complications, and relative immobility during treatment. Tolvaptan in
      addition to diuretic therapy has been shown to improve the amount of volume removed compared
      to diuretic alone.

      The study proposes to compare the strategy of adding tolvaptan to usual care with
      ultrafiltration as primary mode of therapy in acute decompensated HF(ADHF) patients.

      Hypothesis: addition of tolvaptan to usual care for hospitalized HF patients will result in:

        -  greater volume and weight reduction compared with usual care

        -  similar efficacy outcomes compared with ultrafiltration, with less complications of
           therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design is a prospective randomized open labeled and unblinded comparison of two
      different approaches to volume removal. Enrolled patients will be evaluated for target weight
      to be removed. Patients will be randomized to usual care (UC), usual care plus tolvaptan
      (UC+T) or ultrafiltration (UF), within 12 hours of presentation.

      Treatment in the UC and UC+T arms will begin with a furosemide bolus(double the home dose or
      if unavailable, 60mg) and continue with a drip(10 or 20 mg/hr). In addition the UC+T group
      will be treated with tolvaptan 30 mg orally once daily.

      Patients in the UF arm will be treated with UF administered through a brachial line or a
      catheter in the internal jugular vein. Loop and thiazide diuretics will be discontinued,
      although aldosterole antagonists will be continued.

      Urinary neutrophil gelatinase associated lipocalcin(uNGAL)levels are elevated in renal
      dysfunction and may be a sensitive biomarker to distinguish between intrinsic renal damage
      and reversible, transient prerenal azotemia.Characterizing the changes in uNGAL levels during
      the course of ADHF therapy, in comparison with patient weight, BUN and creatinine levels is
      an important step in establishing the role of this potential promising biomarker in ADHF
      treatment strategies.

      Protocol highlights for all patients include:

      Baseline labs and daily through day 4 and at discharge(BMP, BNP, CBC, urine creatinine and
      sodium, uNGAL)

        -  Daily am weights

        -  Daily volume status:total intake, urine output, ultrafiltrate volume

        -  Collect all urine and ultrafiltrate in a 24 hour collection bag, record volume,
           creatinine and Na levels

        -  length of stay

        -  hospital day 4: Minnesota Living with Heart Failure questionnaire

        -  Cost of hospitalization
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net change in weight</measure>
    <time_frame>day 1,2,3,4,5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>net volume loss</measure>
    <time_frame>day 1,2,3,4,5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary NGAL</measure>
    <time_frame>Day 1,2,3,4,5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyspnea score</measure>
    <time_frame>baseline and day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP change from admission to discharge</measure>
    <time_frame>baseline and day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine change</measure>
    <time_frame>Day 1,2,3,4,5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum sodium and potassium changes</measure>
    <time_frame>baseline through day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>day 4 of hospital stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause readmission</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause death</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>nursing intensity</measure>
    <time_frame>day 1,2,3,4,5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>peripheral vs. central access, number of filters used, complications of heparin use</measure>
    <time_frame>day 1,2,3,4,5</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV loop diuretics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care plus tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV loop diuretic plus Tolvaptan 30 mg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ultrafiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volume removal through a brachial line extended length catheter or a quad lumen catheter via the internal jugular vein</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loop diuretic</intervention_name>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_label>Usual care plus tolvaptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolvaptan</intervention_name>
    <arm_group_label>Usual care plus tolvaptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrafiltration</intervention_name>
    <arm_group_label>ultrafiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 of 3 physical exam findings of volume overload (rales, JVP over 5 cm and edema)

          -  BNP over 300

          -  no contraindication to ultrafiltration (line insertion, heparin use)

        Exclusion Criteria:

          -  serum creatinine &gt; 3mg/dL or Na &gt; 145

          -  inotrope or vasopressor dependency

          -  active infection, including urinary tract

          -  resynchronization therapy or coronary intervention in past 30 days

          -  life expectancy less than 6 months

          -  hypertrophic obstructive cardiomyopathy with peak resting gradient &gt; 20 mmHg

          -  IV contrast or NSAID use in the past 1 week (uNGAL related requirement)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene S Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Christ Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Eugene Chung</investigator_full_name>
    <investigator_title>Eugene S. Chung MD, FACC</investigator_title>
  </responsible_party>
  <keyword>Treatment options for acute decompensated heart failure</keyword>
  <keyword>Ultrafiltration</keyword>
  <keyword>tolvaptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Tolvaptan</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

